Lyell Immunopharma Files 8-K on Executive Changes
Ticker: LYEL · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
TL;DR
Lyell Immunopharma's 8-K details director/officer changes and compensation as of Oct 31, 2025.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on November 3, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing covers events up to October 31, 2025, and includes standard corporate governance and executive compensation disclosures.
Why It Matters
This filing provides insight into potential shifts in Lyell Immunopharma's leadership and executive compensation, which can impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding board and executive appointments and departures, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 001-40502 — SEC File Number (Identifies the company's filing history with the SEC.)
- 83-1300510 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- October 31, 2025 (date) — Date of earliest event reported
- November 3, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 201 Haskins Way, South San Francisco, CA 94080 (address) — Principal Executive Offices
FAQ
What specific items are covered in this 8-K filing by Lyell Immunopharma, Inc.?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is October 31, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed as of November 3, 2025.
What is Lyell Immunopharma, Inc.'s state of incorporation and principal executive office address?
Lyell Immunopharma, Inc. is incorporated in Delaware and its principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.
What is the SEC file number for Lyell Immunopharma, Inc.?
The SEC file number for Lyell Immunopharma, Inc. is 001-40502.
Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2025-11-03 08:30:18
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL Nasdaq Glo
Filing Documents
- d73457d8k.htm (8-K) — 24KB
- 0001193125-25-261753.txt ( ) — 131KB
- lyel-20251031.xsd (EX-101.SCH) — 3KB
- lyel-20251031_lab.xml (EX-101.LAB) — 17KB
- lyel-20251031_pre.xml (EX-101.PRE) — 11KB
- d73457d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date: November 3, 2025 By: /s/ Mark Meltz Mark Meltz General Counsel and Corporate Secretary